MOTS-c side effects and safety: what is known and what is not

MOTS-c side effects in people are largely unknown. FDA found no clinical studies of MOTS-c itself and concluded that "potential safety risks associated with the use of MOTS-c-related BDSs in humans are unknown" (FDA briefing document, 2026). The one trial of a related drug, the analog CB4211, reported injection-site reactions as its common side effect. Programs start at $199 a month; see MOTS-c prices.

Below: what the CB4211 trial reported, what FDA's review found, the blood sugar and drug interaction cautions one program lists, quality risks, and what to ask your prescriber. Compounded drugs are not FDA-approved, and the HHS policy that allows MOTS-c compounding is interim and can be withdrawn; we checked it on 30 October 2026.

What the CB4211 trial reported

CB4211 is a modified analog of MOTS-c developed by CohBar. It is the only MOTS-c-related drug we found tested in a registered human trial.

Three limits matter here. The results are company-reported topline figures, not a peer-reviewed paper. The treatment phase lasted four weeks in 20 people, far too small and short to find uncommon or long-term problems. And CB4211 is a different molecule from the MOTS-c a pharmacy compounds, so its safety record does not transfer directly.

What FDA found in its 2026 review

FDA reviewed MOTS-c before its July 2026 Pharmacy Compounding Advisory Committee meeting. The key findings:

• No human data: "The nomination did not include, and FDA has not identified, any clinical studies or human exposure data for MOTS-c via any route of administration" (FDA briefing).
• No toxicity studies: FDA "did not identify nonclinical toxicity studies to inform safety considerations for potential clinical uses of MOTS-c" (FDA briefing).
• No adverse event reports, with a caveat: FDA's searches of its adverse event database "retrieved no reports", but the same document notes "Compounders under section 503A of the FD&C Act generally do not report adverse events to FDA" (FDA briefing). No reports is not the same as no problems.
• Immune reactions: "FDA is concerned about potential for immunogenicity when administered by an injection ROA as proposed, due to the potential for aggregation" (FDA briefing). An immune response to an injected peptide can range from harmless antibodies to a serious reaction, and can blunt the peptide's effect.

FDA also noted the evidence that MOTS-c works came from preclinical studies, and that its molecular targets are unknown, which makes it hard to predict which organs it might affect.

Blood sugar and drug interactions

MOTS-c was discovered as a regulator of insulin sensitivity, and CB4211 lowered glucose more than placebo in the company's figures. Low blood sugar is therefore a reasonable concern, though no trial has measured it for compounded MOTS-c.

Superpower, the program we list, says on its MOTS-c page that "MOTS-c's safety in humans has not been established, and its potential side effects and longer-term risks are not fully understood" (Superpower). It tells patients to contact their care team for "new fatigue, injection-site reactions, rash, dizziness, shakiness, sweating, weakness or confusion" and warns "Some of these symptoms can indicate low blood sugar and need clinical attention" (Superpower).

Under its current protocol, "MOTS-c is not offered to people who are taking, or have taken within the past three months, a GLP-1 medication, metformin or an SGLT2 inhibitor" (Superpower). The same page says the three-month window is the program's own rule and asks patients not to stop a prescribed medicine to qualify. These are one program's precautions, not trial findings.

Quality risks

FDA called both forms of MOTS-c not well characterized, partly because impurity, aggregate and endotoxin data were missing from the published literature (FDA briefing). Product quality is therefore a real part of the risk.

The HHS policy addresses part of this with conditions on sourcing and testing. In Superpower's summary of the policy, "Ingredients must come from FDA-registered manufacturers that meet current good manufacturing practice requirements" (Superpower). We could not read the policy appendix itself, because hhs.gov returned HTTP 403 to our reader. The Federal Register notice says HHS "may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises" (Federal Register, FR Doc. 2026-22192).

Vials sold "for research use" skip the prescription, the licensed pharmacy and these sourcing rules. Our compounded peptide safety guide and research vs prescription peptides cover what to check.

Who should be cautious

• People taking insulin, sulfonylureas or other glucose-lowering drugs, given the blood sugar concern.
• People who are pregnant or breastfeeding: no human safety data exist.
• Anyone with a history of cancer or a serious chronic illness: no long-term or toxicity data exist to reassure them.
• Tested athletes: MOTS-c is on the WADA Prohibited List, as our MOTS-c overview explains.

What to ask your prescriber

• Which pharmacy compounds the product, and whether it is a 503A pharmacy using an FDA-registered ingredient maker.
• Which labs they check before and during treatment, and how often.
• How your current medicines, especially diabetes drugs, change the advice.
• What symptoms mean stop and call, and how to report a reaction to FDA's MedWatch program.

Your prescriber sets the form and schedule; we do not publish doses. Compare what each program includes on the best peptide programs page.

FAQ

What are the MOTS-c side effects?

Nobody knows the full list, because MOTS-c itself has not been tested in a published human trial. Its analog CB4211 caused mild to moderate injection-site reactions and no serious events in a small four-week study, according to the company. Superpower asks patients to report fatigue, rash, dizziness, shakiness, sweating, weakness or confusion.

Is MOTS-c safe?

Safety is not established. FDA concluded in 2026 that potential safety risks in humans are unknown, found no toxicity studies, and raised concerns about immune reactions to an injected peptide. Compounded MOTS-c is not FDA-approved, so quality depends on the pharmacy and its ingredient supplier.

Can MOTS-c cause low blood sugar?

Possibly. MOTS-c was discovered as a regulator of insulin sensitivity, and CB4211 lowered glucose against placebo in company-reported results. Superpower warns that shakiness, sweating, weakness or confusion can signal low blood sugar, especially with glucose-lowering drugs, fasting or exercise. No trial has measured this for compounded MOTS-c.

Can I take MOTS-c with semaglutide or metformin?

One program says no. Superpower does not offer MOTS-c to anyone taking, or who took within three months, a GLP-1 medicine, metformin or an SGLT2 inhibitor. That is its own rule, not an established safe interval. Never stop a prescribed medicine to qualify; ask the clinician who prescribes it.

Does MOTS-c cause cancer?

Unknown. FDA did not find toxicity studies of MOTS-c, and no human study has followed people long enough to look. There is no evidence that it causes cancer, and none that it does not. Anyone with a cancer history should ask an oncologist before starting.

Are there long-term side effects of MOTS-c?

Unknown. The longest treatment period in the CB4211 trial was four weeks. Superpower's page says longer-term risks are not fully understood and that monitoring cannot establish long-term safety. If a seller says long-term use is proven safe, ask for the study.

Compare prescription MOTS-c programs on price, labs and oversight on our best peptide programs page, or see every plan on the price table.